Brown Brothers Harriman & Co. Acquires 45 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Brown Brothers Harriman & Co. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 527 shares of the biopharmaceutical company’s stock after purchasing an additional 45 shares during the period. Brown Brothers Harriman & Co.’s holdings in Regeneron Pharmaceuticals were worth $375,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in REGN. Norges Bank bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $802,036,000. Amundi increased its stake in shares of Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after buying an additional 487,489 shares during the period. Loomis Sayles & Co. L P raised its holdings in Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock valued at $1,122,168,000 after buying an additional 393,997 shares during the last quarter. Proficio Capital Partners LLC boosted its position in Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after buying an additional 219,162 shares during the period. Finally, Worldquant Millennium Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth $127,489,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on REGN. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Wells Fargo & Company dropped their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Robert W. Baird cut their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. JPMorgan Chase & Co. decreased their target price on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a report on Monday. Finally, UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $966.88.

Regeneron Pharmaceuticals Stock Down 0.5 %

NASDAQ REGN opened at $634.23 on Tuesday. The stock’s 50-day moving average price is $682.93 and its 200-day moving average price is $791.84. The company has a market capitalization of $69.34 billion, a P/E ratio of 16.57, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $618.51 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the company earned $11.86 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.56%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.